Melissa Marcum, LPN in Ryegate, VT - Licensed Vocational Nurse

Melissa Marcum, LPN is a Licensed Vocational Nurse based in Ryegate, Vermont. Melissa Marcum is licensed to practice in Vermont (license number 0250007641) and her current practice location is 149 S Bailey Hazen Rd, Ryegate, Vermont. She can be reached at her office (for appointments etc.) via phone at (802) 584-4679.

NPI number for Melissa Marcum is 1356556260 and her current mailing address is 406 Jefferson Rd, Whitefield, New Hampshire. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1356556260.

Contact Information

	Melissa Marcum, LPN
	149 S Bailey Hazen Rd, Ryegate, VT 05042
	(802) 584-4679
	Not Available

Provider's Profile

Full Name	Melissa Marcum
Gender	Female
Speciality	Licensed Vocational Nurse
Location	149 S Bailey Hazen Rd, Ryegate, Vermont
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1356556260
Provider Enumeration Date: 05/14/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Melissa Marcum such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1356556260	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
164X00000X	Licensed Vocational Nurse	0250007641 (Vermont)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Melissa Marcum is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Melissa Marcum, LPN 406 Jefferson Rd, Whitefield, NH 03598-3125 Ph: (603) 837-2388	Melissa Marcum, LPN 149 S Bailey Hazen Rd, Ryegate, VT 05042 Ph: (802) 584-4679

News Archive

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

A drug which was originally developed to treat leukaemia and other cancers of the immune system offers substantial improvements over existing treatments in reducing relapse rates for people with multiple sclerosis (MS), even when they have not responded well to first-line treatment, according to the results of two phase 3 trials published Online First in The Lancet.

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

Non-carriers do not have increased risk of breast cancer due to familial mutation

A population-based analysis of more than 3,000 families including women with breast cancer has found that close relatives of women who carry mutations in a BRCA gene - but who themselves do not have such genetic mutations - do not have an increased risk of developing breast cancer compared to relatives of women with breast cancer who do not have such mutations.

Genetically modified bacterial treatment approach reduces or eliminates sleeping sickness

A tag team of two bacteria, one of them genetically modified, has a good chance to reduce or even eliminate the deadly disease African trypanosomiasis, or sleeping sickness, researchers at Oregon State University conclude in a recent mathematical modeling study.

Survey: 54% of men opt for prostate cancer screening test despite risks

A survey of men age 40 to 74 found that 54 percent said that they would still opt for a popular prostate cancer screening test despite recent recommendations that the test not be performed, finds a new study in American Journal of Preventive Medicine. Only 13 percent said they would choose not to be tested.

Melissa Marcum, LPN - Licensed Vocational Nurse in Ryegate, VT